Treatment of epistaxis in hereditary hemorrhagic telangiectasia patients by argon plasma coagulation with local anesthesia.
BACKGROUND
Recurrent epistaxis is the most common manifestation of hereditary hemorrhagic telangiectasia (HHT). The aim of this study was to determine the role and efficacy of argon plasma coagulation (APC) in the management of epistaxis caused by HHT.


METHODS
From 1997 to 2004, 43 patients with diagnosed HHT were treated for recurrent epistaxis with APC in our department.


RESULTS
Thirty-six patients reported substantial reduction of bleeding after treatment. Of the 18 patients who previously needed blood transfusions, 13 reported substantial reduction of bleeding after treatment and no blood transfusions were necessary.


CONCLUSIONS
APC allows a control of epistaxis in HHT patients and guarantees a long time free from blood transfusions. This treatment modality can be performed with local anesthesia, is not invasive, is well tolerated, is inexpensive, and can be used as a first step even in patients who need to undergo several blood transfusions for their epistaxis.
Pagella
Fabio
F
Clinica Otorinolaringoiatrica, IRCCS Policlinico S. Matteo, Università di Pavia, Italy.
Semino
Lucia
L
Olivieri
Carla
C
Corno
Sabrina
S
Dore
Roberto
R
Draghi
Ferdinando
F
Lanzarini
Luca
L
Vespro
Valentina
V
Buscarini
Elisabetta
E
Danesino
Cesare
C
D000328:Adult; D000368:Aged; D000772:Anesthesia, Local; D001128:Argon / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects*; D004844:Epistaxis / Q000188:drug therapy / Q000209:etiology / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000150:complications*; D016896:Treatment Outcome
D001128:Argon